Osteoporosis 2016

No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise. And while the efficacy and safety of denosumab (Prolia) have now been followed out to 10 years in a large clinical trial, the rate of use of bone-strengthening medica...

What's new in Osteoporosis 2016: Odanacatib, Abaloparatide, Romosozumab

Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.

Comments are closed.